当前位置: X-MOL 学术Nat. Cancer › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
Nature Cancer ( IF 23.5 ) Pub Date : 2021-08-12 , DOI: 10.1038/s43018-021-00232-6
Lucile Vanhersecke 1, 2 , Maxime Brunet 2, 3 , Jean-Philippe Guégan 4 , Christophe Rey 4 , Antoine Bougouin 5 , Sophie Cousin 3 , Sylvestre Le Moulec 6 , Benjamin Besse 7 , Yohann Loriot 7 , Mathieu Larroquette 2, 3 , Isabelle Soubeyran 1 , Maud Toulmonde 3 , Guilhem Roubaud 3 , Simon Pernot 3 , Mathilde Cabart 3 , François Chomy 3 , Corentin Lefevre 3 , Kevin Bourcier 3 , Michèle Kind 8 , Ilenia Giglioli 5 , Catherine Sautès-Fridman 5 , Valérie Velasco 1 , Félicie Courgeon 4 , Ezoglin Oflazoglu 9 , Ariel Savina 9 , Aurélien Marabelle 7 , Jean-Charles Soria 7 , Carine Bellera 10 , Casimir Sofeu 10 , Alban Bessede 4 , Wolf H Fridman 5 , François Le Loarer 1, 2 , Antoine Italiano 2, 3, 7
Affiliation  

Only a minority of patients derive long-term clinical benefit from anti-programmed cell death protein 1 (anti-PD-1) or anti-programmed death-ligand 1 (anti-PD-L1) monoclonal antibodies. The presence of tertiary lymphoid structures (TLSs) has been associated with improved survival in several tumor types. Here, using a large-scale retrospective analysis of three independent cohorts of patients with cancer who were treated with anti-PD-1 or anti-PD-L1 antibodies, we show that the presence of mature TLSs was associated with improved objective response rates, progression-free survival and overall survival, independent of PD-L1 expression status and CD8+ T cell density. These results pave the way for using TLS detection to select patients who are more likely to benefit from immune checkpoint blockade.



中文翻译:

成熟的三级淋巴结构预测免疫检查点抑制剂在实体瘤中的疗效,与 PD-L1 表达无关

只有少数患者从抗程序性细胞死亡蛋白 1(抗 PD-1)或抗程序性死亡配体 1(抗 PD-L1)单克隆抗体中获得长期临床益处。三级淋巴结构 (TLS) 的存在与几种肿瘤类型的生存率提高有关。在这里,使用对接受抗 PD-1 或​​抗 PD-L1 抗体治疗的三个独立癌症患者队列的大规模回顾性分析,我们表明成熟 TLS 的存在与客观缓解率的提高有关,无进展生存期和总生存期,与 PD-L1 表达状态和 CD8 + T 细胞密度无关。这些结果为使用 TLS 检测选择更有可能从免疫检查点阻断中受益的患者铺平了道路。

更新日期:2021-08-12
down
wechat
bug